

Product Characterization Sheet HH1085/HH1086



Human Hepatocytes, Catalog Number 82006

Classification

Grade	Highest Quality: 999Elite™	
Plateability	Plateable	
Viability	>90 %	
Confluency	>90 %	
Culture Duration	>9 Days	
P450 Inducibility	Inducible (CYP1A2, CYP2B6, CYP3A4)	
Transporter activity	CDFDA efflux qualified	
	Pravastatin uptake qualified	

Donor Demographics

Gender	Female	
Age	77 years	
Race	Hispanic	
Cause of death	CVA 2 nd to ICH	
BMI	30.3	
Smoking	No	
Alcohol	No	
Substance abuse	No	
Medical history	Asthma, HTN	
Infectious diseases	es HBV-, HCV-, HIV-, CMV+	

Post-thaw Viability and Yield

Viability	94 %	
Yield	4.2 million	

Storage condition: Hepatocytes are recommended to be stored at < -160°C in the vapor phase of a liquid nitrogen storage unit.

<u>Characterization:</u> Hepatocytes were thawed using 37°C UCRM[™] and centrifuged for 10 minutes at 100g. After removing the supernatant, hepatocytes were re-suspended in UPCM[™] and counted for viability and yield using the Trypan Blue exclusion method. Cells were plated in a hand-coated collagen 24-well plate at a 0.7 million cells per mL density, 0.5 mL per well, and allowed to attach 4-6 hours prior to a Matrigel® overlay.

P450 Induction

Drug Metabolizing Enzyme	Inducer (μΜ)	Substrate (μΜ)	Incubation Time (minutes)	Fold Induction (Gene Expression)	Fold Induction (Activity)
CYP1A2	Omeprazole (50)	Phenacetin (100)	30	46.41 ± 4.48	5.62 ± 0.07
CYP2B6	Phenobarbital (1000)	Bupropion (500)	30	7.72 ± 0.72	2.4 ± 0.8
CYP2C8	Rifampin (20)	Paclitaxel (20)	30	4.333 ± 1.57	
CYP2C9	Rifampin (20)	Diclofenac (25)	30	2.660 ± 0.422	
CYP2C19	Rifampin (20)	S-mephenytoin (250)	30	1.634 ± 0.240	
CYP3A4	Rifampin (20)	Testosterone (200)	30	24.70 ± 5.18	13.0 ± 0.3

<u>CYP450 Induction Assessment:</u> 96 well cultures at a cell density of 0.7 million hepatocytes/mL (56,000 hepatocytes/well) were used in the CYP450 induction assessment. The hepatocytes were cultured as collagen-Matrigel® sandwich for 1 day followed by treatment duration of 48-72 hours for mRNA and 72 hours for activity using known enzyme inducers. Induction in CYP450 activity was assessed by quantifying respective metabolite formation by LC-MS/MS. Gene expression was quantified by RT-PCR. Values reflect mean and standard deviation of triplicate treatments (N=3).

Drug Metabolism Activity

Drug Metabolizing Enzyme	Substrate (μΜ)	Incubation Time (minutes)	Metabolite Quantified	Activity (pmol/minute/million cells)
CYP1A2	Phenacetin (100)	15	Acetaminophen	54.7
CYP2A6	Coumarin (50)	30	7-Hydroxycoumarin	37.0
CYP2B6	Bupropion (500)	15	Hydroxybupropion	10.8
CYP2C8	Paclitaxel (20)	15	6α-Hydroxypaclitaxel	2.4
CYP2C9	Diclofenac (25)	15	4-Hydroxydiclofenac	92.2
CYP2C19	S-Mephenytoin (250)	30	4-Hydroxymephenytoin	10.0
CYP2D6	Dextromethorphan (15)	15	Dextrorphan	25.7
CYP2E1	Chlorzoxazone (250)	15	6-Hydroxychlorzoxazone	34.7
CVD2A4	Midazolam (20)	10	1-Hydroxymidazolam	44.5
CYP3A4	Testosterone (200)	15	6β-Hydroxytestosterone	470.7
ECOD	7-Ethoxycoumarin (100)	30	7-Hydroxycoumarin	102.6



Product Characterization Sheet HH1085/HH1086



Human Hepatocytes, Catalog Number 82006

UGT	7-Hydroxycoumarin (100)	30	7-Hydroxycoumarin glucuronide	395.0
Sulfotransferase	7-Hydroxycoumarin (100)	30	7-Hydroxycoumarin sulfate	21.0

<u>CYP450 Activity Assessment:</u> The hepatocytes were incubated at a cell density of 0.5 million cells/mL in a 48-well plate (125,000 hepatocytes/well) for the designated time durations with isoform-selective substrates. The metabolites were identified and analyzed using LC-MS/MS.


Pravastatin Uptake Transporter Activity

Pravastatin	Pravastatin with Rifampin	% Inhibition by
(pmol/10 ⁶ Cells)	(pmol/10 ⁶ Cells)	Rifampin
0.812	0.31	62 %


<u>Pravastatin Uptake Assessment:</u> 96 well cultures at a cell density of 0.7 million hepatocytes/mL (56,000 hepatocytes/well) were used in the Pravastatin Uptake Assessment. After approximately 6 hours in culture, the hepatocytes were treated with and without 20 uM Rifampin for a pre-incubation time of 30 minutes. Following pre-incubation, 25 uM pravastatin with and without rifampin was incubated for a duration time of 6 minutes. Values reflect the mean of triplicate treatments (N=3). The metabolites were identified and analyzed using LC-MS/MS.

Photomicrographs (100X, Phase Contrast)


Phase Contrast Day 2




Phase Contrast Day 5



Phase Contrast Day 9



Efflux Transporter Assessment



Monolayer Comments: HH1085/HH1086 has high attachment efficiency and a confluency of 90-100 % by 24 hours. This lot exhibits excellent morphology and remains intact for over 9 days in culture.

Efflux Transporter Assessment: The hepatocytes were cultured at a cell density of 0.7 million hepatocytes/mL in a 12-well plate as a collagen-Matrigel® sandwich. On day 5, the hepatocytes were treated with incubation medium containing 5 µM carboxy-2′,7′ dichlorofluorescein diacetate (CDFDA) and imaged on fluorescein isothiocyanate (FITC) fluorescent filter to assess bile canalicular formation.



Product Characterization Sheet HH1085/HH1086



Human Hepatocytes, Catalog Number 82006

IVAL cell culture media and tissue culture plates used in this evaluation:

- Recovery of thawed hepatocytes Cat. No. 81015 UCRM™ Universal Cryopreservation Recovery Media, 50 mL tube
- Initial plating of hepatocytes Cat. No. 81016 UPCM™ Universal Primary Cell Plating Media, 50 mL tube
- Sandwich culture with 0.25 mg Matrigel® Cat. No. 81018/81019 HIM™ Hepatocyte Induction Media, 50 mL tube/500 mL bottle
- Suspension and incubation of hepatocytes Cat. No. 81039/81040 HQM™ Hepatocyte Incubation Media, 50 mL tube/500 mL bottle
- Collagen coated plates Cat. No. 71006, 71008 CellAffix™ 24-well and 96-well Collagen Hand Coated tissue culture plate, 5 plates per pack.

To inquire about our products and services or for technical questions please contact:

• In Vitro ADMET Laboratories by phone at +1 (866) 458-1094 or +1 (410) 869-9037 or email at info@invitroadmet.com